Search

Cell-based immunotherapies, particularly lab-produced immune cells known as CAR T cells, show promise in treating various cancers. But how do we produce effective ones? Gaetano Gargiulo from the Max Delbrück Center will develop a novel screening tool, supported by an ERC Proof of Concept Grant.

From 2024, the Federal Government and the State of Berlin will fund the establishment of the National Center for Tumor Diseases (NCT) Berlin. The new site is a cooperation between DKFZ and Charité, BIH, and Max Delbrück Center aimed at closely integrating clinical and translational cancer research.

The Berlin biotech Glycotope and the Max Delbrück Center have signed an agreement to explore the potential of combining Glycotope’s tumor-specific antibodies with CAR technology developed by the Max Delbrück Center. Their common goal: advancing immunotherapies against solid tumors.

After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse want to use novel CAR T-cell therapies to help patients with cancers that are currently untreatable.

Internationally renowned for pioneering achievements and geared to inter-institutional cooperation: 22 research groups at the Berlin Institute for Medical Systems Biology in the Max Delbrück Center (MDC-BIMSB) explore how genes regulate life. It is now celebrating its 15th birthday.

The herpes simplex virus-1 can sometimes cause a dangerous brain infection. Combining an anti-inflammatory and an antiviral could help in these cases, report scientists with the Rajewsky and Landthaler labs and the Organoid Platform at the Max Delbrück Center in “Nature Microbiology.”

The Max Delbrück Center in Berlin and Heidelberg University will found a new Helmholtz Institute for Translational AngioCardioScience (HI-TAC) in Mannheim and Heidelberg. The Helmholtz Senate voted in favor of the institute, which will integrate vascular biomedicine, systems biology and heart research.

Neuroblastoma is the third most common malignancy in children. 16 labs at the Max Delbrück Center and other Berlin-based researchers will investigate how they originate and grow in a new Collaborative Research Centre. The project, supported by the German Research Foundation (DFG), has been granted approximately €13.5 million.

While CAR-T cells have proven successful in treating certain types of leukemia and lymphoma, these immunotherapies can become even more effective. A clinical trial run by Charité and the Max Delbrück Center has been awarded a grant of several million euros to test a new approach.

The pianist SooJin Anjou and the scientist Nikolaus Rajewsky are both experts in their respective fields. Together, they have created the event series “Spark”: a concert and meet-up for creative people, an exploration to learn from both sides. On March 13th, the series continued at MDC-BIMSB.